Deucravacitinib for Psoriasis
(POETYK PSO-LTE Trial)

Recruiting in Palo Alto (17 mi)

+389 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Bristol-Myers Squibb

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.

Eligibility Criteria

This trial is for people who have completed a prior Phase 3 study of BMS-986165 for moderate-to-severe psoriasis. Women participants should not be pregnant, breastfeeding, or lactating. Individuals with any condition that could interfere with the study or those showing active symptoms of tuberculosis are excluded.

Inclusion Criteria

Completion of the protocol-required treatment period in an applicable study of BMS-986165 in moderate-to-severe psoriasis

I am not pregnant, lactating, or breastfeeding.

Exclusion Criteria

I do not have any signs or symptoms of tuberculosis.

Any disease or medical condition that the investigator feels would make the patient unsuitable for this study

Treatment Details

Interventions

Deucravacitinib (BMS-986165) (Janus Kinase (JAK) Inhibitor)

Trial OverviewThe focus is on Deucravacitinib (BMS-986165), assessing its long-term safety and effectiveness in individuals who've previously taken part in a related Phase 3 trial for treating psoriasis.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: BMS-986165Experimental Treatment1 Intervention